Immuneering Corporation (IMRX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Immuneering Corporation (IMRX) Earnings Overview
As of June 13, 2026, Immuneering Corporation (IMRX) reported trailing twelve-month net income of -$54M, reflecting +37.7% year-over-year growth. The company earned $-1.24 per diluted share over the past four quarters.
Looking at the long-term picture, IMRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2019.
Immuneering Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), INVA ($504M net income, 63.8% margin), PRTA (-$151M net income, -2520.6% margin), IMRX has comparable earnings metrics. Compare IMRX vs ACAD →
IMRX Earnings vs Peers
Earnings metrics vs comparable public companies
IMRX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$56M | +8.2% | -$59M | $-1.27 | - | - |
| 2024 | -$61M | -14.1% | -$64M | $-2.04 | - | - |
| 2023 | -$53M | -5.9% | -$58M | $-1.88 | - | - |
| 2022 | -$51M | -50.6% | -$52M | $-1.87 | -15937.3% | -16325.8% |
| 2021 | -$34M | -96.8% | -$34M | $-1.27 | -1612.3% | -1629.2% |
| 2020 | -$17M | -121.0% | -$17M | $-1.26 | -737.2% | -739.0% |
| 2019 | -$8M | - | -$6M | $-0.60 | -401.6% | -327.7% |
Download Data
Export IMRX earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in IMRX back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in IMRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMRX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowIMRX — Frequently Asked Questions
Quick answers to the most common questions about buying IMRX stock.
What is IMRX earnings per share (EPS)?
IMRX trailing twelve-month (TTM) diluted EPS is $-1.24, reflecting +37.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Immuneering Corporation's net income?
Immuneering Corporation (IMRX) trailing twelve-month net income is $-54M as of 2025. Earnings grew +37.7% year-over-year.
Is IMRX profitable?
IMRX is not currently profitable on a TTM basis, reporting a net loss of $-54M. Net margin is N/A. Investors should monitor for a return to profitability.
What is IMRX's earnings growth rate?
IMRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are IMRX's profit margins?
Immuneering Corporation net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -43.1%.
Is IMRX growing earnings?
Yes, IMRX earnings are accelerating — EPS growth of +37.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-54M. Earnings momentum is strengthening.
What was IMRX's best earnings year?
Immuneering Corporation's highest annual net income on record is $-8M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were IMRX's earnings last quarter?
IMRX's most recent reported quarter was Q1 2026. Net income was $-13M with diluted EPS of $-0.21. For a full breakdown of all quarters, see the quarterly earnings table on this page.